— Akebia Therapeutics (NASDAQ: AKBA) reported fourth quarter 2019 loss of $0.79 per share vs. expected loss of $0.47 per share.
— Revenue rose 16% to $69.6 million vs. $93.15 million expected.
— Net product revenue more than quadrupled to $28.9 million from $6.8 million in the fourth quarter of 2018.
— R&D expenses were $80.4 million for the fourth quarter of 2019 compared to $87.1 million for the fourth quarter of 2018.
— Akebia continues to expect to share the data from global Phase 3 studies of its anemia treatment drug Vadadustat in the second quarter of 2020.
— AKBA stock dipped more than 5% in the pre-market trading session.
Most Popular
Docusign (DOCU) Earnings: 3Q26 Key Numbers
Docusign, Inc. (NASDAQ: DOCU) reported its earnings results for the third quarter of 2026. Revenue increased 8% year-over-year to $818.4 million. GAAP net income was $83.7 million, or $0.40
Infographic: How Ulta Beauty (ULTA) performed in Q3 2025
Ulta Beauty, Inc. (NASDAQ: ULTA) reported its earnings results for the third quarter of 2025. Net sales increased 12.9% year-over-year to $2.9 billion, driven by comparable sales growth, the Space
Hewlett Packard Enterprise (HPE) Earnings: 4Q25 Key Numbers
Hewlett Packard Enterprise (NYSE: HPE) reported revenue of $9.7 billion for the fourth quarter of 2025, up 14% from the prior-year period in actual dollars and in constant currency. Net
